| Literature DB >> 32201578 |
Bérénice Lutz1, Claudia Lehner1, Kira Schmitt2, Barbara Willi2, Gertraud Schüpbach3, Meike Mevissen4, Ruth Peter5, Cedric Müntener5, Hanspeter Naegeli5, Simone Schuller1.
Abstract
BACKGROUND: Antimicrobial resistance is an increasing problem in human and veterinary medicine and is closely linked to the use of antimicrobials. The objective of this study was to describe antimicrobial prescriptions for selected canine diseases in Switzerland during 2016.Entities:
Keywords: antimicrobial resistance; antimicrobial stewardship; dogs; prescribing habits
Year: 2020 PMID: 32201578 PMCID: PMC7064144 DOI: 10.1136/vetreco-2019-000370
Source DB: PubMed Journal: Vet Rec Open ISSN: 2052-6113
Inclusion and exclusion criteria and search terms for the surveyed indications
| Indication | Included | Excluded | Search terms |
| Acute diarrhoea | Diarrhoea <3 weeks. Acute haemorrhagic diarrhoea syndrome (AHDS). Parasitic diarrhoea. Non-specific diarrhoea. | Diarrhoea >3 weeks or relapsing. Diarrhoea related to drug administration or another extradigestive disease. Diarrhoea that appeared during hospitalisation. Parvovirosis. | Diarrhoea, colitis, duodenitis, enteritis, ileitis, gastritis, AHDS, haemorrhagic gastroenteritis and Giardia, watery stools. |
| Urinary tract infection | Suspicion or diagnosis of bacterial cystitis. Suspicion or diagnosis of pyelonephritis. | Glomerulonephritis. Leptospirosis. Urolithiasis without signs of bacteriuria. | Urinary tract infection, dysuria, difficult urination, stranguria, haematuria, bloody urine, blood in urine, polyuria, pollakiuria, pyelonephritis, inflammation of the bladder, cystitis, bladder and urinalysis. |
| Respiratory tract infection | Aspiration pneumonia. Pneumonia (bacterial, viral and unknown). Bronchitis. Kennel cough. | Nasal infections. Fungal infections. Neoplasia of the respiratory tract. Lung worms. | Respiratory tract infection, respiratory tract disease, cough, tracheitis, tracheobronchitis, pneumonia, inflammation of the lungs, bronchitis, bronchopneumonia, kennel cough, distemper, influenza, adenovirus, dyspnoea and tachypnoea. |
| Wound infection | Bite wound. Abscess. | Anal gland abscess. Dental abscess. Abscess due to a foreign body. Hotspot. | Wound infection, abscess, purulent wound and bite. |
Criteria used to judge appropriate use of antimicrobials based on national and international recommendations7–9 28
| Indication | Comment | Antimicrobial | Dosage (mg/kg) | Application frequency | Treatment duration (days) |
| Acute diarrhoea | Antimicrobial therapy NOT indicated unless clinical suspicion of sepsis based on clinical and laboratory data.* | Ampicillin | 20 | Twice daily/three times a day | 5–7 |
| Amoxicillin | 11–15 | Twice daily/three times a day | 5–7 | ||
| Amoxicillin/clavulanic acid | 12.5–20 | Twice daily/three times a day | 5–7 | ||
| Ampicillin/sulbactam‡ | 30 | Twice daily/three times a day | 5–7 | ||
| If suspicion of sepsis* and no improvement with initial therapy after two to three days, antimicrobial spectrum may be extended by adding. | Enrofloxacin OR | 10–20 | Once daily | 5–7 | |
| Marbofloxacin AND/OR | 2 | Once daily | 5–7 | ||
| Metronidazole | 15 | Twice daily | 5–7 | ||
| UTIs | According to 2011 guidelines, complicated UTIs are defined as infections caused by anatomical or functional changes or disorders of the immune system, recurrent UTI /three times per year or more) or UTI in non-castrated male. | Sporadic (uncomplicated) UTI | |||
| Amoxicillin | 11 – 15 | Twice daily/three times a day | 5 – 7 | ||
| Ampicillin† | 20 | Twice daily/three times a day | 5–7 | ||
| Complicated UTI | |||||
| Amoxicillin | 11–15 | Twice daily/three times a day | 5–28 | ||
| Amoxicillin/clavulanic acid | 12.5–20 | Twice daily/three times a day | 5–28 | ||
| Ampicillin† | 2020 | Twice daily/three times a day | 5–28 | ||
| Ampicillin/sulbactam‡ | 30 | Twice daily/ | 5–28 | ||
| Trimethoprim/sulfadiazin | 15 | Twice daily | 5–28 | ||
| Trimethoprim/sulfamethoxazole | 15 | Twice daily | 5–28 | ||
| Once daily | |||||
| Enrofloxacin | 10–20 | Once daily | 5–42 | ||
| Marbofloxacin | 2 | Twice daily | 5–42 | ||
| Trimethoprim/sulfadiazin | 15 | Twice daily | 5–28 | ||
| Trimethoprim/sulfamethoxazole | 15 | 5–28 | |||
| Respiratory tract infections | Aspiration pneumonia or bacterial bronchopneumonia. | Mild to moderate disease | Treatment 1 week beyond resolution of clinical/radiographic signs | ||
| Doxycycline | 10 | Once daily | |||
| Amoxicillin/clavulanic acid | 12.5–20 | Twice daily/three times a day | |||
| Ampicillin/sulbactam‡ | 30 | Twice daily/three times a day | |||
| Amoxicillin/clavulanic acid OR | 12.5–20 | Twice daily/three times a day | |||
| Ampicillin/sulbactam‡ | 30 | Twice daily/three times a day | |||
| AND | |||||
| Enrofloxacin OR | 10–20 | Once daily | |||
| Marbofloxacin | 2 | Once daily | |||
| Kennel cough: antimicrobial therapy only indicated if: poor general condition, rectal T>39.4°C or signs of lower airway involvement. | Doxycycline | 10 | Once daily | 5–14 | |
| Wound infections | Bite wounds: antimicrobial therapy always indicated, except damage limited to epidermis. | Amoxicillin/clavulanic acid | 12.5–20 | Abscesses or superficial¶ bite wounds: 5–7. | |
| Twice daily | |||||
| Cefalexin | 20–35 | Twice daily/three times a day | Deep** or penetrating bite wounds: 7–10. | ||
| Clindamycin | 10–15 | Twice daily |
*Sepsis criteria used: lethargy plus at least one of the following: body temperature >39.4°C, heart rate >140/min, WBC <4 or >25×109/l and banded neutrophils >1.5×109/l.
†Intravenous or subcutaneous.
‡Intravenous.
§Severe clinical, laboratory or radiographic signs.
¶Only skin damaged.
**Skin and deeper structures damaged.
UTI, urinary tract infection.
Modified justification score used to judge the accordance of antimicrobial prescriptions in dogs33
| Justification score | Criteria |
| JS-1 | Empirical treatment in accordance with national and international recommendations, that is, correct indication, antimicrobial class, dosage and treatment duration |
| JS-2 | Wrong dosage and/or duration of treatment. |
| JS-3 | Wrong antimicrobial class. |
| JS-4 | Decision to treat NOT in accordance with guidelines, that is, antibiotic prescription when not indicated or no antibiotic prescription although indicated. |
Characteristics of 1065 dogs presented for acute diarrhoea, suspected or confirmed urinary tract infections, respiratory tract infections or wound infections to university hospitals or private practices
| Parameter | Acute diarrhoea | Urinary tract infections | Respiratory tract infections | Wound infections | ||||||
| University hospitals | Private practices | P value* | University hospitals | Private practices | P value* | University hospitals | Private practices | P value* | Private practices | |
| 165 | 206 | 70 | 175 | 108 | 166 | 175 | ||||
| 0.4 | 0.2 | 0.3 | ||||||||
| Female, n (%) | 74 (45) | 99 (48) | 39 (56) | 112 (64) | 56 (52) | 73 (44) | 91 (52) | |||
| Male, n (%) | 91 (55) | 102 (50) | 31 (44) | 61 (35) | 52 (48) | 91 (55) | 81 (46) | |||
| Unknown, n (%) | 0 | 5 (2) | 0 | 2 (1) | 0 | 2 (1) | 3 (2) | |||
| Age (years), median (IQR) | 5 (2–8) | 6 (1–9) | 0.5 | 10 (6–12) | 8 (3.3–10.8) | 0.02 | 6 (2–11) | 7 (2–11) | 09 | 6 (3–9.5) |
| Weight (kg), median (IQR) | 10 (8–13) | 13 (10–17) | 0.03 | 18 (13–23) | 21 (16–25) | 14 (9–19) | 11 (9–17) | 0.8 | 21 (11–28) | |
| 0.2 | 0.6 | 0.07 | ||||||||
| Purebred, n (%) | 140 (85) | 165 (80) | 58 (83) | 136 (76) | 93 (86) | 133 (80) | 133 (76) | |||
| Mixed breed, n (%) | 22 (13) | 38 (18) | 12 (17) | 35 (20) | 11 (10) | 31 (19) | 40 (23) | |||
| Unknown, n (%) | 3 (2) | 3 (2) | 0 | 4 (3) | 4 (4) | 2 (1) | 2 (1) | |||
*Statistically significant P values after Bonferroni correction (P<0.02) are written in bold characters.
Diagnostic work-up and antibiotic prescriptions in 371 cases of canine acute diarrhoea cases presented to university hospitals or private practices
| Parameter | University hospitals | Private practices | P value* |
| Total number of cases | 165 | 206 | |
| Minimal diagnostic work-up, n (%)† | |||
| Yes | 131 (79) | 12 (6) | |
| No | 34 (20) | 194 (94) | |
| Sepsis criteria fulfilled, n (%)‡ | |||
| Yes | 34 (21) | 21 (10) | 0.08 |
| No | 129 (78) | 134 (65) | |
| Unknown | 2 (1) | 51 (25) | |
| Haemorrhagic diarrhoea, n (%) | |||
| Yes | 101 (61) | 52 (25) | |
| No | 64 (39) | 132 (64) | |
| Unknown | 0 (0) | 22 (11) | |
| Hospitalisation, n (%) | |||
| Yes | 141 (85) | 9 (4) | |
| No | 24 (15) | 197 (96) | |
| Pretreated, n (%) | |||
| Yes | 24 (15) | 0 (0) | |
| No | 138 (84) | 194 (94) | |
| Unknown | 3 (1) | 12 (6) | |
| Antibiotic therapy, n (%) | |||
| Yes | 116 (70) | 127 (62) | 0.08 |
| Antibiotic classes, n (%) | |||
| Potentiated aminopenicillins | 55 (47) | 13 (10) | |
| Nitroimidazole | 74 (64) | 100 (79) | 0.5 |
| Non-potentiated aminopenicillins | 0 (0) | 9 (6) | 0.007 |
| Third-generation cephalosporins | 0 (0) | 3 (2) | 0.1 |
| Tetracyclines | 0 (0) | 3 (2) | 0.1 |
| Fluoroquinolones | 3 (3) | 15 (12) | 0.01 |
| Combination therapy, n (%) | |||
| Yes | 11 (9) | 6 (5) | 0.1 |
| No | 105 (91) | 121 (95) | |
| HPCIA, n (%)§ | |||
| Yes | 3 (3) | 18 (14) | 0.004 |
| No | 113 (97) | 109 (86) | |
| Duration of therapy (days) | |||
| Median (IQR) | 8 (7–9) | 6 (5–7) | |
| Justification score, n (%) | |||
| 1 | 57 (35) | 62 (30) | 0.4 |
| 2 | 5 (3) | 0 (0) | 0.01 |
| 3 | 15 (9) | 3 (1) | |
| 4 | 88 (53) | 102 (50) | 0.5 |
| Judgement not possible | 1 (0.6) | 39 (19) | |
*Statistically significant P values after Bonferroni correction are written in bold characters.
†Minimal work-up is CBC.
‡Criteria fulfilled if lethargic and at least one of the following: body temperature >39.4°C, heart rate >140/min, WBC <4 or >25×109/l and band neutrophils >1.5×109/l.
§HPCIA: highest priority critically important antimicrobials include third-generation or higher generation cephalosporins, quinolones, macrolides, ketolides, glycopeptides and polymyxins.
CBC, complete blood count; WBC, white blood cell.
Diagnostic work-up and antibiotic prescriptions in 245 dogs with suspected UTIs presented to university hospitals or private practices
| Parameter | University hospital | Private practice | P value* |
| Number of cases | 70 | 175 | |
| Microscopic sediment analysis, n (%) | |||
| Yes | 59 (84) | 73 (42) | |
| No | 11 (16) | 81 (46) | |
| Bacterial culture, n (%) | |||
| Yes | 67 (96) | 43 (25) | |
| No | 3 (4) | 132 (75) | |
| UTI considered complicated, n (%)*† | |||
| Yes | 48 (69) | 46 (26) | |
| Bacteriuria, n (%)†‡ | |||
| Confirmed | 62 (88) | 27 (15) | |
| Excluded | 7 (10) | 22 (13) | |
| No enough data to confirm or exclude bacterial aetiology | 1 (2) | 126 (72) | |
| Hospitalisation, n (%) | |||
| Yes | 40 (56) | 5 (3) | |
| No | 30 (44) | 170 (97) | |
| Pretreated, n (%) | |||
| Yes | 14 (20) | 6 (3) | |
| No | 54 (77) | 162 (93) | |
| Unknown | 2 (3) | 7 (4) | |
| Antibiotic therapy | |||
| Yes | 68 (97) | 147 (84) | 0.3 |
| No | 2 (3) | 28 (16) | |
| Antibiotic classes, n (%) | |||
| Potentiated aminopenicillins | 53 (78) | 97 (65) | 0.07 |
| Fluoroquinolones | 12 (17) | 43 (29) | 0.07 |
| Non-potentiated aminopenicillins | 5 (7) | 22 (15) | 0.2 |
| First-generation cephalosporins | 2 (3) | 11 (7) | 0.2 |
| Third-generation cephalosporins | 0 (0) | 3 (2) | 0.2 |
| Lincosamide | 2 (3) | 0 (0) | 0.02 |
| Amphenicols | 1 (1) | 0 (0) | 0.1 |
| Potentiated sulfonamides | 1 (1) | 0 (0) | 0.1 |
| Combination therapy, n (%) | |||
| Yes | 5 (7) | 0 (0) | |
| No | 63 (93) | 147 (100) | |
| HPCIA‡§ | |||
| Yes | 11 (16) | 47 (32) | 0.03 |
| No | 57 (84) | 100 (68) | |
| Duration of therapy (days) | |||
| Median (IQR) | 18 (10–27) | 11 (7–14) | |
| Justification score, n (%) | |||
| 1 | 38 (54) | 11 (6) | |
| 2 | 4 (6) | 1 (0.5) | 0.01 |
| 3 | 13 (19) | 17 (10) | 0.06 |
| 4 | 14 (20) | 25 (14) | 0.3 |
| Judgement not possible | 1 (1) | 121 (69) | |
*Statistically significant P values after Bonferroni correction are written in bold characters
†Complicated UTI defined according to previous guidelines as infections in the presence of anatomical or functional changes or disorders of the immune system, recurrent UTI (three times per year or more) and UTI in non-castrated males.28
‡Defined as either positive microscopic sediment analysis or positive bacterial culture.
§HPCIA: highest priority critically important antimicrobials include third-generation or higher generation cephalosporins, quinolones, macrolides, ketolides, glycopeptides and polymyxins.
UTI, urinary tract infection.
Diagnostic work-up and antibiotic prescriptions in 274 dogs with respiratory tract infections presented to university hospitals or private practices
| Parameter | University hospital | Private practice | P value* |
| Number of cases | 108 | 166 | |
| Duration of clinical signs, n (%) | |||
| <7 days | 49 (45) | 49 (30) | 0.03 |
| >7 days | 34 (31) | 15 (9) | |
| Unknown | 25 (23) | 102 (61) | |
| Minimal work-up, n (%)† | |||
| Yes | 75 (69) | 1 (0.6) | |
| Broncho-alveolar lavage and culture, n (%) | |||
| Yes | 8 (7) | 2 (1) | 0.007 |
| Cases judged severe, n (%)‡ | |||
| Yes | 25 (24) | 1 (0.6) | 0.7 |
| No | 3 (3) | 0 (0) | |
| Impossible to judge | 80 (73) | 165 (99.4) | |
| Diagnosis based on clinical signs in addition to, n (%) | |||
| Clinical examination alone | 15 (14) | 145 (87) | |
| Clinical examination and radiographs | 72 (66) | 16 (10) | |
| Clinical examination, radiographs (optional) and bronchoscopy | 12 (11) | 6 (4) | 0.014 |
| Clinical examination, radiographs (optional), bronchoscopy and BAL | 8 (7) | 2 (1) | 0.007 |
| Hospitalisation, n (%) | |||
| Yes | 69 (54) | 1 (0.6) | |
| No | 39 (36) | 165 (99.4) | |
| Pretreated, n (%) | |||
| Yes | 41 (37) | 7 (4) | |
| No | 66 (62) | 158 (95.4) | |
| Unknown | 1 (1) | 1 (0.6) | |
| Antibiotic therapy, n (%) | |||
| Yes | 82 (76) | 89 (49) | |
| No | 26 (24) | 77 (51) | |
| Antibiotic classes, n (%) | |||
| Potentiated aminopenicillins | 59 (71) | 58 (65) | 0.3 |
| Tetracyclines | 12 (15) | 26 (29) | 0.03 |
| Non-potentiated aminopenicillins | 2 (2) | 33 (37) | |
| Fluoroquinolones | 23 (28) | 4 (4) | |
| First-generation cephalosporins | 4 (5) | 0 (0) | |
| Third-generation cephalosporins | 1 (1) | 3 (3) | 0.4 |
| Combination therapy, n (%) | |||
| Yes | 18 (22) | 4 (5) | |
| No | 64 (88) | 85 (95) | |
| HPCIA§ | |||
| Yes | 25 (30) | 7 (8) | |
| No | 57 (70) | 82 (92) | |
| Duration of therapy (days) | |||
| Median (IQR) | 12.7 (3–20) | 6.3 (0–10) | |
| Justification score, n (%) | |||
| 1 | 68 (63) | 64 (39) | |
| 2 | 1 (1) | 3 (2) | 0.6 |
| 3 | 15 (14) | 11 (7) | 0.04 |
| 4 | 19 (18) | 45 (27) | 0.06 |
| Judgement not possible | 5 (5) | 43 (26) |
*Statistically significant P values after Bonferroni correction are written in bold characters.
†Minimal work-up consist of a thoracic radiograph and CBC.
‡Cases were judged as severe if there was a reduced general state+signs of SIRS (systemic inflammatory response syndrome)/sepis/left-shift+pulmonary involvement (radiographs or auscultation).
§HPCIA: highest priority critically important antimicrobials include third-generation or higher generation cephalosporins, quinolones, macrolides, ketolides, glycopeptides and polymyxins.
BAL, broncho-alveolar lavage; CBC, complete blood count.
Presence of clinical signs and antibiotic prescription in 175 dogs with wound infections presented to private practices
| Parameter | Private practice, n (%) |
| Number of cases | |
| 175 | |
| Type of lesion | |
| Abscess | 40 (23) |
| Bite | 135 (77) |
| Local wound treatment | |
| Yes | 113 (65) |
| No | 14 (8) |
| Unknown | 48 (27) |
| Drain placed | |
| Yes | 14 (8) |
| No | 161 (92) |
| Antibiotic therapy | |
| Yes | 157 (90) |
| No | 18 (10) |
| Antibiotic classes | |
| Potentiated aminopenicillins | 132 (75) |
| Non-potentiated aminopenicillins | 54 (31) |
| First-generation cephalosporins | 18 (10) |
| Fluoroquinolones | 5 (3) |
| Third-generation cephalosporins | 2 (1) |
| Lincosamide | 1 (0.5) |
| Penicillins | 0 (0) |
| Combination therapy | |
| Yes | 3 (2) |
| HPCIA* | |
| Yes | 7 (4) |
| Duration of therapy: days (IQR) | 7.6 (5.9–10) |
| Justification score | |
| 1 | 105 (60) |
| 2 | 26 (15) |
| 3 | 6 (3) |
| 4 | 28 (16) |
| Judgement not possible | 10 (6) |
*HPCIA: highest priority critically important antimicrobials include third-generation or higher generation cephalosporins, quinolones, macrolides, ketolides, glycopeptides and polymyxins.